ACRES Launches Outreach and Education Blog
The ACRES' Accountable Research Blog is being piloted in the San Antonio, Texas market, and is projected to be extended to other Hearst media markets, both domestically and internationally.
The Alliance for Clinical Research Excellence and Safety (ACRES) and Texas-based for-profit San Antonio Express-News, an affiliate of Hearst Communications, have formed a strategic alliance to create a blog as a vehicle for public outreach and education across the healthcare and clinical research endeavor. The blog is directed toward patients and the public. The ACRES' Accountable Research Blog is being piloted in the San Antonio, Texas market, and is projected to be extended to other Hearst media markets, both domestically and internationally. In addition, the alliance partners will work together to develop and use the blog to conduct surveys on important research issues, to gather public feedback and provide educational blog opportunities to stakeholders in healthcare and biomedical research.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
